Legend Biotech Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LEGN research report →
Range $40 – $78
Price Chart
About the company
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
- CEO
- Alan S. Bash
- IPO
- 2020
- Employees
- 3,300
- HQ
- Somerset, NJ, US
Get TickerSpark's AI analysis on LEGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.82B
- P/E
- -1533.50
- Fwd P/E
- 185.76
- PEG
- -8.25
- P/S
- 2.09
- P/B
- 2.25
- EV/EBITDA
- 25.54
- Div Yield
- 0.00%
- Gross Margin
- 56.98%
- Op Margin
- 2.51%
- Net Margin
- -0.02%
- ROE
- -0.02%
- ROIC
- -0.02%
Latest fiscal year · YoY change
- Revenue
- $1.03B+64.0%
- Gross Profit
- $620.80M+58.1%
- Op Income
- $-136,500,000
- Net Income
- $-296,800,000-67.7%
- EPS
- $-1.60-64.9%
- OCF Growth
- +30.2%
- FCF Growth
- -6.3%
- 52W High
- $37.50
- 52W Low
- $15.14
- 50D MA
- $19.24
- 200D MA
- $22.18
- Beta
- 0.40
- RSI (14)
- 32
- Avg Volume
- 2.23M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Legend Biotech posted strong CARVYKTI growth and better-than-expected profitability, while highlighting earlier-line momentum, encouraging in vivo CAR-T data, and a revised gross margin outlook.· November 10, 2026
- CARVYKTI net trade sales rose about 36% year over year to $710 million, with 19% U.S. growth and 86% ex-U.S. growth.
- Earlier-line use is increasing: second- and third-line patients were 50% of U.S. apheresis volume, up from 41% in Q1 2026 and 29% in Q1 2025.
- Gross margin improved to 58%, above expectations, and management now expects Q4 gross margin on net product sales in the high 50% range.
- Adjusted net income was $55.6 million, or $0.14 per diluted share, versus an adjusted net loss of $18.7 million, or $(0.05) per share, a year ago.
- Management reiterated confidence in achieving company-wide profitability for full-year 2026 on an adjusted net income basis.
Total revenue increased 32% year over year, driven by CARVYKTI demand and commercial expansion. CARVYKTI net trade sales increased approximately 36% year over year to approximately $710 million. Gross margin was 58%, compared with management’s prior expectation in the lower 50% range, and Q4 gross margin on net product sales is expected to be in the high 50% range. Adjusted net income was $55.6 million, or $0.14 per diluted share, versus an adjusted net loss of $18.7 million, or $(0.05) per diluted share, in the same period last year. R&D expense declined 16% year over year, SG&A declined 20% and included a $24 million one-time share-based compensation credit, and operating margin improved to positive 6% excluding that credit versus negative 16% in Q3 2025. The company ended the quarter with approximately $853 million in cash, cash equivalents and time deposits and no long-term debt. Management expects substantial year-over-year global growth, continued CARVYKTI share gains, and full-year 2026 company-wide profitability on an adjusted net income basis; for Q4, management said sales consensus appears to be at the higher end of its current scenario range, citing slower-than-expected U.S. earlier-line share growth and launch timing outside the U.S. Management also said it expects double-digit CARVYKTI growth in 2027, though current 2027 consensus is also at the higher end of its scenario range.
Ingrid Zhang used her first earnings call as CEO to emphasize continuity and confidence, saying Legend has built a strong foundation in science, manufacturing, and patient focus that can support the rest of the pipeline. Her priorities are to maximize CARVYKTI, advance next-generation programs, and strengthen execution to deliver sustained profitability. She struck an upbeat but disciplined tone, framing the quarter as proof that the company is executing across commercial, clinical, and operational fronts.
Carlos Santos focused on leverage and profitability: he said revenue growth is driving improving operating margins and adjusted earnings, with gross margin at 58% versus expectations in the lower 50% range. He highlighted a 16% decline in R&D, a 20% decline in SG&A that included a $24 million one-time share-based compensation credit, and a positive 6% operating margin excluding that credit versus negative 16% last year. He also pointed to $853 million in cash and time deposits, no long-term debt, and unchanged capital allocation priorities centered on investing in cell therapy and the in vivo platform while staying disciplined.
Analysts pressed on the timeline and potential of LB2501, and management said the ASH update will include an expanded data cut with 19 patients, more follow-up, and additional details at the conference; Yuhong Qiu noted 100% ORR and CR at dose level 2 and more than 60% ORR/CR at dose level 3, with no DLT, ICANS, or non-ICAN neurotoxicity reported in the abstract. A key commercial concern was why stronger earlier-line adoption is not translating more directly into U.S. sales growth; Alan Bash said the shift is real but competitive pressure from bispecifics and the education-heavy referral cycle mean growth will take time. Management also said CARTITUDE-5 could read out no sooner than 2027, CARTITUDE-6 would be later, and that CAR-T before bispecifics is the preferred sequence for patients based on NCCN guidance.
The call showed CARVYKTI still growing strongly globally, with early-line adoption increasing and management saying there is still a large pool of patients not previously exposed to BCMA. Management believes NCCN guideline support, a growing body of long-term data, and expanding ex-U.S. markets can sustain growth toward the product’s $5 billion-plus potential. On top of that, Legend is advancing a new in vivo CAR-T platform with encouraging early data and FDA clearance of LB2501’s IND.
Management acknowledged that U.S. earlier-line share growth is slower than previously expected and that current sales consensus for 2027 sits at the high end of its scenario range because of launch timing delays outside the U.S. and competitive pressure from bispecifics and other CAR-Ts. The company also said key frontline CARVYKTI studies are event-driven, with CARTITUDE-5 not expected to read out until at least 2027, which leaves a longer period before those data can potentially expand the franchise. LB2501 remains early, with management emphasizing that more follow-up, more patients, and further dose exploration are still needed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.3%
- Shares Outstanding
- 184.94M
- Float Shares
- 178.18M
of shares held by institutions
230 13F filers
Buy/sell ratio 4.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 24.20M | ▼ 4.90M |
| Deerfield Management Company, L.P. | 8.14M | ▲ 450.00K |
| Montanova Capital, LLC | 7.07M | ▼ 511.03K |
| Hhlr Advisors, Ltd. | 5.98M | 0 |
| Westfield Capital Management Co LP | 5.15M | ▲ 720.08K |
| Blackrock, Inc. | 5.09M | ▲ 367.22K |
| Goldman Sachs Group Inc | 3.66M | ▲ 2.20M |
| Point72 Asset Management, L.P. | 3.08M | ▼ 809.89K |
| Kynam Capital Management, LP | 3.00M | ▲ 1.42M |
| State Street Corp | 1.62M | ▲ 120.68K |
| Artisan Partners Limited Partnership | 1.56M | ▼ 695.05K |
| Morgan Stanley | 1.51M | ▲ 119.68K |
Held by 417 ETFs
Biggest fund positions in LEGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Salovey Peter | buy | 10,000 |
| Nov 12, 26 | Salovey Peter | buy | 10,000 |
| Sep 29, 26 | Sanders Corazon (Corsee) D. | sell | 27,370 |
| Sep 24, 26 | Salovey Peter | other | 28,330 |
| Sep 24, 26 | Heyman Tomas J. | other | 20,986 |
| Sep 24, 26 | Mao Li | other | 20,986 |
| Sep 24, 26 | Casey Patrick John | other | 20,986 |
| Sep 24, 26 | Ji Darren Xiaohui | other | 28,330 |
| Sep 24, 26 | Sanders Corazon (Corsee) D. | other | 20,986 |
| Sep 21, 26 | Santos Carlos E | other | 19,676 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LEGN coverage
Recent articles, reports, and earnings notes.

Inside the Obsidian Therapeutics IPO: Reverse-Merger Setup, Risks, and Watchpoints
Obsidian Therapeutics, Inc. Common Stock (NASDAQ: OBX) is expected to list on 2026-08-04, but the price range has not been disclosed. The company is coming to market through an all-stock reverse merger with Galera Therapeutics rather than a traditional IPO. Bull case: a differentiated cell-therapy platform with strong strategic backing; bear case: no disclosed pricing, no commercial revenue, and heavy clinical risk.

What to Watch as SL Science Holding Limited Prices on Nasdaq
SL Science Holding Limited Ordinary Shares (SLBT) is expected to list on Nasdaq on 2026-06-15, but the price range has not been disclosed. This is a de-SPAC listing rather than a traditional IPO, so the key question is whether the market gives credit to a small-revenue biotech platform with a very large headline valuation.
Want a deeper read on LEGN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Legend Biotech: The Market Is Missing The Bigger Picture
seekingalpha.com · Nov 17
Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What Legend Biotech (LEGN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
globenewswire.com · Nov 10
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
globenewswire.com · Nov 4
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
zacks.com · Oct 29
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
zacks.com · Oct 27
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.